Avascular jaw osteonecrosis associated with bisphophonate therapy;Osteonecrosi avascolare del massiccio facciale in corso di terapia con bisfosfonati

Recenti Progressi in Medicina

Volumn 97, Issue 3, 2006, Pages 140-144

  Broglia, Chiara ^a   Merlati, Giuseppe ^a   Valentino, Francesco ^a   Benatti, Chiara ^a   Gobbi, Paolo ^a,b   Ascari, Edoardo ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Avascular osteonecrosis; Bisphosphonates; Multiple myeloma

Indexed keywords

ALPHA INTERFERON; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; DEXAMETHASONE; DICOUMAROL; DOXORUBICIN; MELPHALAN; NADROPARIN; PAMIDRONIC ACID; THALIDOMIDE; VINCRISTINE; ZOLEDRONIC ACID;

AGED; ANTIANGIOGENIC ACTIVITY; ARTICLE; AVASCULAR JAW OSTEONECROSIS; AVASCULAR NECROSIS; CASE REPORT; CLINICAL FEATURE; DIAGNOSTIC IMAGING; DRUG EFFECT; DRUG SUBSTITUTION; HUMAN; IMAGE ANALYSIS; IMMUNOGLOBULIN A MYELOMA; JAW DISEASE; LONG TERM CARE; MALAISE; MULTIPLE MYELOMA; PATHOGENESIS; SOMNOLENCE; SYMPTOM; VERTIGO;

AGED; DIPHOSPHONATES; HUMANS; JAW DISEASES; MALE; MULTIPLE MYELOMA; OSTEONECROSIS;

EID: 33646000835     PISSN: 00341193     EISSN: 00341193     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Berenson JR, Hillner BE, Kyle RA, et al. American Society of Clinical Oncology Clinical Practice Guidelines: The role of bisphosphonates in multiple myeloma. J Clin Oncol 2002; 20: 3719-36.
2. Jantunen E. Bisphosphonate therapy in multiple myeloma: past, present, future. Eur J Haematol 2002; 69: 257-64.
3. Ali SM, Esteva FJ, Hortobagyi G. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol 2001; 19: 3434-7.
4. Marx RE. Pamidronate (Aredia) and Zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115-7.
5. Migliorati CA: Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 2003; 21: 4253-4.
6. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62: 527-34.
7. Bagan JV, Murillo J, Ymenez Y, et al. Avascular jaw Osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med 2005; 34: 120-3.
8. Lugassy G, Shaham R, Nemets A, Ben-Dor D, Nahlieli O. Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity. Am J Med 2004; 117: 440-1.
9. Aramany MA. Basic principles of obturator design for partially edentulous patients. Part I: Classification. J Prosthet Dent 2001; 86: 559-61.
10. Aramany MA. Basic principles of obturator design for partially edentulous patients. Part II: Design principles. J Prosthet Dent 2001; 86: 562-8.
11. Neville-Webbe HL, Holen I, Coleman RE: The anti-tumour activity of bisphosphonates. Cancer Treat Rev 2002; 28: 305-19.
12. Kapitola J, ZaK J. Effect of pamidronate on bone blood flow in oophorectomized rats. Physiol Res 1998; 47, 237-40.
13. Santini D, Vincenzi B, Avvisati G, et al. Pamidronate induces modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 2002; 8: 1080-4.
14. Santini D, Vespasiani Gentilucci U, Vincenzi B, et al.: The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 2003; 14: 1468-76.